Medtronic

Valiant™ Thoracic Stent Graft with the Captivia™ Delivery System



Five-year results: Dissection Trial

TEVAR in Acute, Complicated Type B Dissection¹



of patients treated with Valiant Captivia system achieved positive and sustained aortic remodeling through five years

89% (16/18) achieved sustained aortic remodeling, with false lumen thrombosis and true lumen expansion increasing over time in this challenging patient cohort (94% DeBakey class IIIB)

Sustained aortic remodeling



true lumen diameter increase/stable and true lumen volume increase – with 92.3% (24/26) true lumen diameter increase/stable already achieved at three years²



complete false lumen thrombosis¹



proximal entry tears fully excluded³

Key highlights through five years



No instances of postimplant rupture



No conversions to open repair for the descending aortic dissection



No aortic ruptures




No core lab reported type lb endoleaks

Low RTAD incidence through one year in complicated TBAD*



Results are taken from independent clinical studies for illustration purposes only and are not based on statistical analysis. Results may differ in a head-to-head comparison; multiple factors contribute to clinical study outcomes and need to be considered in making assessments across different studies.

Five-year freedom from dissection-related mortality





freedom from type la endoleak through 5 years

Three core lab reported type la endoleaks over the 5 years: two were detected at six-month follow-up and neither needed reintervention



Trial quick facts

Objective

Evaluate the clinical performance of the Valiant Captivia thoracic stent graft system for the treatment of acute, complicated Type B aortic dissections.

Study design



Prospective, non-randomized, multicenter trial with the Valiant Captivia Thoracic Stent Graft System



16 U.S. centers



n = 50 patients with acute, complicated(malperfusion, rupture) Type B aortic dissection



Primary endpoint: all-cause mortality within 30 days of index procedure

Clinical status at onset

94%

DeBakey class IIIB dissections (46/49)

869

Malperfusion

20%

Rupture (10/50)

References

- ™Third party brands are trademarks of their respective owners.
- *RTAD incidence from leading competitor stent grafts is not intended for cross-study comparison of different stent grafts or patient cohorts.
- ¹Bavaria JE, Brinkman WT, Hughes GC, et al. Five-year outcomes of endovascular repair of complicated acute type B aortic dissections. *J Thorac Cardiovasc Surg*. Published online May 13, 2020.
- ²Lim CY, et al. Endovascular Repair in Acute Complicated Type B Aortic Dissection: 3-Year Results from the Valiant US Investigational Device Exemption Study. *Korean J Thorac Cardiovasc Surg*. 2017 June;50(3):137-143.
- ³ Bavaria J, Brinkman W, Hughes C, et al. Outcomes of Thoracic Endovascular Aortic Repair in Acute Type B Aortic Dissection: Results From the Valiant United States Investigational Device Exemption Study. *Ann Thorac Surg.* September 2015;100(3):802-808.
- ⁴Lombardi JV, Cambria RP, Nienaber CA, et al. Prospective multicenter clinical trial (STABLE) on the endovascular treatment of complicated type B aortic dissection using a composite device design. *J Vasc Surg*. 2012 Mar;55(3):629-640.e2.
- $^{\rm 5}$ Gore Dissection IDE: Gore cTAG IFU pages 56 and 69

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

Medtronic

Europe

Medtronic International Trading Sàrl. Route du Molliau 31 Case postale CH-1131 Tolochenaz Tel: +41 (0)21 802 70 00 Fax: +41 (0)21 802 79 00